InnoTherapy Inc Cash Flow-to-Debt Ratio
InnoTherapy Inc cash flow-to-debt ratio. InnoTherapy Inc (246960) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of ₩-107.41 Million could theoretically repay 0% of its total liabilities (₩50.78 Billion) in one year. Check 246960 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of InnoTherapy Inc (2015–2024)
Cash flow-to-debt ratio of InnoTherapy Inc from 2015 to 2024. Historical debt coverage capacity for InnoTherapy Inc across 10 annual periods. Check 246960 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
InnoTherapy Inc Cash Flow-to-Debt Ratio by Year (2015–2024)
InnoTherapy Inc cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for InnoTherapy Inc. For the full cash flow conversion analysis, see 246960 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.70x | ₩-5.96 Billion | ₩8.54 Billion | ▼ -178.5% |
| 2023 | -0.25x | ₩-2.82 Billion | ₩11.26 Billion | ▼ -8.4% |
| 2022 | -0.23x | ₩-4.10 Billion | ₩17.77 Billion | ▼ -26.4% |
| 2021 | -0.18x | ₩-3.98 Billion | ₩21.80 Billion | ▲ +72.0% |
| 2020 | -0.65x | ₩-2.87 Billion | ₩4.41 Billion | ▲ +57.1% |
| 2019 | -1.52x | ₩-3.26 Billion | ₩2.15 Billion | ▼ -15.5% |
| 2018 | -1.31x | ₩-2.18 Billion | ₩1.66 Billion | ▲ +35.6% |
| 2017 | -2.04x | ₩-2.26 Billion | ₩1.11 Billion | ▼ -74.1% |
| 2016 | -1.17x | ₩-1.12 Billion | ₩957.90 Million | ▼ -1360.6% |
| 2015 | -0.08x | ₩-1.15 Billion | ₩14.34 Billion | — |